Lensar Earnings Call: Recurring Revenue Shines Amid Disruption

Lensar Inc ((LNSR)) has held its Q4 earnings call. Read on for the main highlights of the call.

Lensar’s latest earnings call painted a cautiously optimistic picture, as management balanced solid operating momentum against the fallout from its terminated acquisition. Recurring revenue and procedure growth remained strong, and the ALLY platform continued to gain share, but merger-related uncertainty weighed on system sales, margins, and international demand. Management framed 2026 as a reset year, with a path back to historical performance.

Recurring Revenue Becomes the Core Engine

Lensar emphasized the strength and stability of its recurring revenue base, which grew 15% year over year to $46.3 million in fiscal 2025. In Q4 alone, recurring revenue climbed 17% to $12.7 million, annualizing above $50 million and representing roughly 79% of quarterly sales, a mix that supports higher margins and smoother visibility for investors.

Procedure Growth Underpins Future Sales

Underlying this recurring stream is robust procedure volume expansion, with global procedures up about 20% in Q4 and 22% for the full year to more than 206,000. Since the ALLY launch, procedure volumes have surged roughly 50% versus 2023, signaling rising adoption and providing a strong foundation for ongoing consumable and service revenue.

ALLY Installed Base and Market Share Surge

The company continued to scale its installed base, ending the year with just over 200 ALLY systems, up about 48% from the prior year. Combined ALLY and LLS systems reached roughly 435, a 13% increase, while U.S. procedure market share jumped from 14% at launch to 23.4%, a gain of around 9.4 percentage points.

Utilization Outperformance Boosts Economics

Lensar also highlighted superior utilization across its systems, a key driver of recurring revenue leverage. U.S. LENSAR lasers perform on average 27% more procedures annually than the national laser average, and ALLY accounts are running at roughly 600 procedures per year, which magnifies consumable pull-through and enhances per-system returns.

Positive Adjusted EBITDA Signals Operating Health

Despite acquisition-related disruption, Lensar posted positive adjusted EBITDA for fiscal 2025, with Q4 adjusted EBITDA of $595,000. Management noted that this performance implies operating cash flow positivity when excluding working capital swings, suggesting the core business remains fundamentally sound even as it transitions past the failed merger.

Balance Sheet Relief After Deal Collapse

The termination of the Alcon deal came with a financial silver lining as Lensar recovered a $10 million transaction deposit, now recorded as cash. The company also negotiated concessions that will eliminate about $4.3 million in unpaid advisor fees and push around $5 million of remaining acquisition liabilities out to May 2027, easing near-term liquidity pressures.

Product Validation and New Customer Wins

Management underscored that the acquisition process itself helped validate the ALLY platform, reinforcing its technology credentials in the marketplace. Nearly half of Q4 system placements were with surgeons who had never used femtosecond lasers before, demonstrating that Lensar is not just taking share but expanding the overall addressable market.

Regulatory Block Ends Alcon Deal

The proposed Alcon acquisition was mutually terminated after regulators signaled they were likely to challenge the transaction. While this underscored the strategic value of Lensar’s assets, it also created more than nine months of uncertainty, during which distributors and customers delayed decisions and commercial momentum temporarily slowed.

International System Sales Slide

That uncertainty hit system sales hardest outside the U.S., where Q4 saw only one ALLY placement versus ten in the same quarter last year. For the full year, system sales slipped to 20 units from 23, with management attributing most of the decline to a slowdown in ex‑U.S. activity as overseas partners paused in the face of the pending deal.

Q4 Revenue Feels the Pressure

Total revenue in Q4 fell 4% year over year to $16.0 million, largely because of weaker system sales, especially internationally. For the full year 2025, revenue still grew 9%, but the Q4 softness reflected the lingering impact of acquisition-related disruption on capital equipment demand even as recurring revenue held up well.

Higher SG&A and Transaction Costs Hit Profitability

Operating expenses swelled under the weight of merger costs, with Q4 SG&A up 51% year over year to $10.3 million and total operating expenses rising 41% to $11.9 million. For 2025, Lensar booked $17.1 million in acquisition-related expenses, roughly $14 million of which remained unpaid at year-end before the negotiated fee forgiveness and deferrals.

Margins Squeezed by Inflation and Tariffs

Gross margin for 2025 slipped to 46% from 48% a year earlier, reflecting inflationary pressures and tariffs that the company chose not to pass on to customers. Management guided fiscal 2026 gross margin to a 46%–49% range, acknowledging that the eventual outcome will depend on the mix between higher-margin recurring revenue and more volatile system sales.

International Rebound Expected to Take Time

Lensar cautioned that rebuilding international momentum will not be immediate, as many overseas distributors adopted a wait-and-see stance during the merger saga. The company expects tenders and distributor-led deals, particularly in Southeast Asia and parts of Europe, to take several quarters to fully restart, suggesting a gradual rather than abrupt recovery abroad.

Guidance Points to Gradual Normalization

Looking ahead to 2026, management is targeting a steady return to historical operating patterns, focused on faster revenue growth, cost discipline, and stronger cash flow. The company expects gross margins between 46% and 49%, plans to limit cash-based operating expense growth to no more than 10%, and aims to reenergize ex‑U.S. distributors to lift system sales, supported by a growing recurring base, positive adjusted EBITDA, and an improved balance sheet.

Lensar’s call presented a company emerging from a complex deal process with its core business intact and growing, even as near-term headwinds remain. Investors will be watching whether strong recurring revenue, rising procedure volumes, and expanding market share can offset international softness and margin pressure as the firm works to reaccelerate system placements and restore its pre-merger rhythm.